Core Points - The Shandong Provincial Science and Technology Conference recently held in Jinan recognized the winners of the 2024 Shandong Provincial Science and Technology Awards, with Binzhou Medical University achieving a record number of awards, including one Youth Award and two Second-Class Progress Awards [1][7] Group 1: Awards and Achievements - Binzhou Medical University won four provincial science and technology awards, including one Shandong Provincial Science and Technology Youth Award, two Second-Class Progress Awards, and one First-Class Technology Invention Award as a participating unit [1] - Professor Tian Geng received the Shandong Provincial Science and Technology Youth Award for establishing advanced platforms for real-time monitoring of cell membrane biological functions and promoting precision diagnosis and treatment technologies for tumors [2] - The Second-Class Progress Award for "Key Technology Innovation and Application of Systematic Characterization and Quality Control of Chemical Components in Traditional Chinese Medicine" was led by Professor Zhang Jiayu, significantly enhancing the discovery of novel trace components in traditional Chinese medicine [3] - Professor Zhang Guilong's project on "High-Resolution Visualization Imaging Technology Innovation and Promotion Application Based on Functional Magnetic Resonance Imaging Probes" also received a Second-Class Progress Award, contributing to non-invasive diagnostic methods for liver damage [4] - The First-Class Technology Invention Award was awarded for the project "Core Key Technology and Application of Novel Dual-Target Receptor-Fc Fusion Protein Drugs," led by Professor Jiang Jing, which developed two globally innovative dual-target fusion protein drugs [5] Group 2: Institutional Focus and Strategy - In recent years, Binzhou Medical University has actively implemented a technology innovation-driven development strategy, focusing on ecological protection and high-quality development in the Yellow River Basin, leveraging its advantages in health and biomedicine [6] - The university has established several distinctive research platforms and gathered strong research teams to support key technological advancements and provide significant support for industrial transformation and upgrading [6] - The university's approach to technology award applications emphasizes early planning and comprehensive support throughout the application process, enhancing the quality of submission materials [6]

会议开幕式由烟台毓璜顶医院党委书记、院长宋西成主持。他表示,胶东国际肿瘤会议秉持"开放共享、 合作创新"的理念,致力于搭建多元、开放的交流平台,构建合作紧密、充满活力的学术共同体。自2016年 创办以来,已经成功召开了六届,其辐射影响力不断扩大,形成了良好的品牌效应。作为肿瘤医学界的年度 盛事,第七届胶东国际肿瘤会议是历届会议参会外籍专家最多、分会场数量最多的一届,在专业深度和国 际化程度上均达到了新的高度,为推动我国乃至全球肿瘤医学事业的发展注入强劲动能。 开幕式上,英国皇家生物学会院士姜文国、英国商业贸易部(中国)健康创新主管冯志豪、英国皇家外科学 院理事会成员兼巡回外科学会(TSS)主席Rachel Hargest、中国科学院院士陈子江亲临现场并发表致辞, 中国科学院院士陈孝平、中国工程院院士于金明通过视频方式发表致辞。嘉宾们的发言站位高远、视域 开阔、思想深邃,激发了全场共鸣,拉开了高水平学术交流的序幕。 孙淑玉 烟台报道 通讯员 李成修 崔方荣 山海相邀,共襄盛会。5月18日,第七届胶东国际肿瘤会议在烟台成功举办。大会设1个主会场、32个平行 分会场。百余位顶尖专家现场授课,他们分别来自英国、德国、 ...

Group 1: Shizai Bio - Shizai Bio's iPSC-derived cell therapy for ALS has received FDA approval for clinical trials, marking it as the first globally and the first from China to gain Orphan Drug Designation [2] Group 2: Burning Stone Medical - Burning Stone Medical has partnered with BGI Genomics to enhance global tumor precision diagnosis, leveraging BGI's sequencing technology and Burning Stone's extensive product portfolio [3][4] Group 3: Jingtai Technology - Jingtai Technology and Guangdong Hengjian Investment announced a project in the Greater Bay Area to develop AI infrastructure, aiming to drive a billion-level AI pharmaceutical materials industry [5][6] Group 4: Tongxin Medical - Tongxin Medical's BrioVAD system has completed its first clinical enrollment in the US, entering a multi-center clinical trial for advanced heart failure [7][8] Group 5: WuXi XDC - WuXi XDC and LigaChem have deepened their collaboration in ADC development, aiming to accelerate the transition of ADC candidates from early research to commercialization [9][10] Group 6: Huayi Lekang - Huayi Lekang's GS1191-0445 injection has entered Phase III clinical trials, marking it as China's first gene therapy for Hemophilia A [12][13] Group 7: Ruike Bio - Ruike Bio's new adjuvanted nine-valent HPV vaccine REC604c has had its clinical trial application accepted, targeting the male market and reducing the required doses from three to two [15] Group 8: Angkuo Pharmaceutical - Angkuo Pharmaceutical's CUSP06 has received FDA Fast Track designation for treating platinum-resistant ovarian cancer, showing promising early clinical results [16] Group 9: Phanes Therapeutics - Phanes Therapeutics has completed the first patient dosing of its dual antibody drug PT217 in combination with chemotherapy for small cell lung cancer [18] Group 10: Jiayue Pharmaceutical - Jiayue Pharmaceutical's JYP0015 has received clinical trial approval for treating RAS-mutant cancers, showing significant efficacy compared to similar drugs [20][22]